These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts. Raggi C; Invernizzi P; Andersen JB J Hepatol; 2015 Jan; 62(1):198-207. PubMed ID: 25220250 [TBL] [Abstract][Full Text] [Related]
8. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma. Ko S; Kim M; Molina L; Sirica AE; Monga SP Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703 [TBL] [Abstract][Full Text] [Related]
9. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine? Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432 [TBL] [Abstract][Full Text] [Related]
10. Intrahepatic cholangiocarcinoma arising in multiple bile duct hamartomas: report of two cases and review of the literature. Xu AM; Xian ZH; Zhang SH; Chen XF Eur J Gastroenterol Hepatol; 2009 May; 21(5):580-4. PubMed ID: 19282767 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of biliary carcinogenesis and growth. Wise C; Pilanthananond M; Perry BF; Alpini G; McNeal M; Glaser SS World J Gastroenterol; 2008 May; 14(19):2986-9. PubMed ID: 18494047 [TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets. Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004 [TBL] [Abstract][Full Text] [Related]
14. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568 [TBL] [Abstract][Full Text] [Related]
15. Future directions in the treatment of cholangiocarcinoma. Zhu AX Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434 [TBL] [Abstract][Full Text] [Related]
16. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications. Wu HJ; Chu PY Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710 [TBL] [Abstract][Full Text] [Related]
17. Effects of liver cirrhosis and patient condition on clinical outcomes in intrahepatic cholangiocarcinoma: a retrospective analysis of 156 cases in a single center. Jesper D; Heyn SG; Schellhaas B; Pfeifer L; Goertz RS; Zopf S; Neurath MF; Strobel D Eur J Gastroenterol Hepatol; 2018 May; 30(5):552-556. PubMed ID: 29280922 [TBL] [Abstract][Full Text] [Related]
18. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Sirica AE; Strazzabosco M; Cadamuro M Adv Cancer Res; 2021; 149():321-387. PubMed ID: 33579427 [TBL] [Abstract][Full Text] [Related]